2 results
Approved WMOPending
Primary Objective• To characterize preliminary targeting properties of [68Ga]-NeoBOMB1 in patients with malignancies known to overexpress GRPR.Secondary objectives• To assess safety and tolerability of a single diagnostic dose of [68Ga]-NeoBOMB1…
Approved WMORecruiting
To assesses the efficacy of Tinlarebant in slowing the rate of growth of atrophic lesion(s) in adolescent subjects with STGD1.